Abstract
Catechol-O-methyltransferase (COMT) catabolises dopamine and is important for regulating dopamine levels in the prefrontal cortex. Consistent with its regulation of prefrontal cortex dopamine, COMT modulates working memory and executive function; however, its significance for other cognitive domains, and in other brain regions, remains relatively unexplored. One such example is reward processing, for which dopamine is a critical mediator, and in which the striatum and corticostriatal circuitry are implicated. Here, we discuss emerging data which links COMT to reward processing, review what is known of the underlying neural substrates, and consider whether COMT is a good therapeutic target for treating addiction. Although a limited number of studies have investigated COMT and reward processing, common findings are beginning to emerge. COMT appears to modulate cortical and striatal activation during both reward anticipation and delivery, and to impact on reward-related learning and its underlying neural circuitry. COMT has been studied as a candidate gene for numerous reward-related phenotypes and there is some preliminary evidence linking it with certain aspects of addiction. However, additional studies are required before these associations can be considered robust. It is premature to consider COMT a good therapeutic target for addiction, but this hypothesis should be revisited as further information emerges. In particular, it will be critical to reveal the precise neurobiological mechanisms underlying links between COMT and reward processing, and the extent to which these relate to the putative associations with addiction.
Keywords: Dopamine, COMT, prediction error, nucleus accumbens, striatum, smoking, Catechol O Methyl Transferase, Prefrontal cortex, COMT gene, Orbitofrontal cortex, valine
CNS & Neurological Disorders - Drug Targets
Title:The Role of Catechol-O-Methyltransferase in Reward Processing and Addiction
Volume: 11 Issue: 3
Author(s): E. M. Tunbridge, A. Huber, S. M. Farrell, K. Stumpenhorst, P. J. Harrison and M. E. Walton
Affiliation:
Keywords: Dopamine, COMT, prediction error, nucleus accumbens, striatum, smoking, Catechol O Methyl Transferase, Prefrontal cortex, COMT gene, Orbitofrontal cortex, valine
Abstract: Catechol-O-methyltransferase (COMT) catabolises dopamine and is important for regulating dopamine levels in the prefrontal cortex. Consistent with its regulation of prefrontal cortex dopamine, COMT modulates working memory and executive function; however, its significance for other cognitive domains, and in other brain regions, remains relatively unexplored. One such example is reward processing, for which dopamine is a critical mediator, and in which the striatum and corticostriatal circuitry are implicated. Here, we discuss emerging data which links COMT to reward processing, review what is known of the underlying neural substrates, and consider whether COMT is a good therapeutic target for treating addiction. Although a limited number of studies have investigated COMT and reward processing, common findings are beginning to emerge. COMT appears to modulate cortical and striatal activation during both reward anticipation and delivery, and to impact on reward-related learning and its underlying neural circuitry. COMT has been studied as a candidate gene for numerous reward-related phenotypes and there is some preliminary evidence linking it with certain aspects of addiction. However, additional studies are required before these associations can be considered robust. It is premature to consider COMT a good therapeutic target for addiction, but this hypothesis should be revisited as further information emerges. In particular, it will be critical to reveal the precise neurobiological mechanisms underlying links between COMT and reward processing, and the extent to which these relate to the putative associations with addiction.
Export Options
About this article
Cite this article as:
M. Tunbridge E., Huber A., M. Farrell S., Stumpenhorst K., J. Harrison P. and E. Walton M., The Role of Catechol-O-Methyltransferase in Reward Processing and Addiction, CNS & Neurological Disorders - Drug Targets 2012; 11 (3) . https://dx.doi.org/10.2174/187152712800672409
DOI https://dx.doi.org/10.2174/187152712800672409 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Vascular Calcification Revisited: A New Perspective for Phosphate Transport
Current Cardiology Reviews Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research Schizophrenia: Redox Regulation and Volume Neurotransmission
Current Neuropharmacology Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications
Current Drug Targets Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry The Role of Neurotrophins in Axonal Growth, Guidance, and Regeneration
Current Neurovascular Research Heme Oxygenase-1 in Lung Disease
Current Drug Targets Methodological Considerations to Understand the Sensory Function of TRP Channels
Current Pharmaceutical Biotechnology Nucleus Accumbens Dopamine and the Forebrain Circuitry Involved in Behavioral Activation and Effort-Related Decision Making: Implications for Understanding Anergia and Psychomotor Slowing in Depression
Current Psychiatry Reviews Pharmacological Effects of Turmeric on Learning, Memory and Expression of Muscarinic Receptor Genes (M1, M3 and M5) in Stress-induced Mouse Model
Current Drug Targets Serum DHEA-S, Testosterone and Cortisol Levels in Female Patients with Schizophrenia
Endocrine, Metabolic & Immune Disorders - Drug Targets HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Metabotropic Glutamate Receptors as Targets for Analgesia: Antagonism, Activation, and Allosteric Modulation
Current Pharmaceutical Biotechnology Subject Index To Volume 13
Current Medicinal Chemistry Apathy: A Conceptual Review
Current Psychiatry Research and Reviews Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Experimental Treatment Options in Absence Epilepsy
Current Pharmaceutical Design Neuregulin Signaling in Pieces-Evolution of the Gene Family
Current Pharmaceutical Design